Pfizer

From Nano World Order - Wiki

Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered in New York City, and one of the largest drug companies in the world by revenue. Founded in 1849, Pfizer has grown through decades of mergers, acquisitions, and drug development into a dominant force in global medicine. Its profile shifted dramatically during the COVID-19 Pandemic when, in partnership with German biotech firm BioNTech, it developed and commercialised the BNT162b2 mRNA vaccine — marketed as Comirnaty — generating over $100 billion in revenue within two years. The mRNA technology at the core of this vaccine was built on foundational nucleoside modification research by biochemists Katalin Karikó and Drew Weissman, whose work Pfizer and BioNTech licensed for commercial deployment. Pfizer's conduct during the pandemic, including its lobbying of regulators, legal efforts to suppress clinical trial data, and the contents of documents released under court order, have attracted sustained scrutiny from independent researchers, legal advocates, and concerned scientists worldwide.

Pfizer global headquarters, New York City

History and Corporate Growth

Pfizer was founded in Brooklyn, New York, by cousins Charles Pfizer and Charles F. Erhart as a fine chemicals business. Its early success came from producing citric acid and, later, large-scale penicillin during World War II — a contract that established Pfizer as a significant industrial pharmaceutical producer.

Throughout the latter half of the 20th century, Pfizer pursued aggressive global expansion, launching blockbuster drugs including Viagra, Lipitor (the best-selling drug in history at the time), Zoloft, and Norvasc. By 2000, Pfizer had become the world's largest pharmaceutical company following its $90 billion acquisition of Warner-Lambert.

Further acquisitions — including Pharmacia (2003) and Wyeth (2009) — consolidated its dominance. These mergers gave Pfizer control over an enormous portfolio of patents, research pipelines, and manufacturing capabilities.

Pfizer is publicly traded on the New York Stock Exchange and is a component of the Dow Jones Industrial Average. Its annual revenues regularly exceed $50 billion, and it employs approximately 80,000 people globally.

BNT162b2: The COVID-19 mRNA Vaccine

In early 2020, Pfizer entered into a development partnership with BioNTech, a German mRNA therapeutics company co-founded by Uğur Şahin and Özlem Türeci. The collaboration focused on rapidly developing an mRNA-based vaccine against SARS-CoV-2.

The Karikó–Weissman Foundation

The mRNA technology underpinning BNT162b2 did not originate within Pfizer or BioNTech's own laboratories. It rests on a foundational scientific breakthrough made by biochemist Katalin Karikó and immunologist Drew Weissman at the University of Pennsylvania in the early 2000s.

Karikó and Weissman discovered that substituting naturally occurring uridine in mRNA molecules with a modified nucleoside — pseudouridine — dramatically reduced the immune system's inflammatory response to synthetic mRNA, making therapeutic mRNA viable for the first time. Prior to their work, the immune system's tendency to attack and degrade foreign mRNA had been a fundamental barrier to the entire field.

Their key findings were published in Immunity in 2005 and in subsequent papers, and the foundational patents were filed through the University of Pennsylvania. These patents were eventually licensed to both Moderna and BioNTech, forming the intellectual backbone of both companies' COVID-19 vaccine products.

Katalin Karikó joined BioNTech in 2013 as a Senior Vice President, playing a direct role in applying nucleoside-modified mRNA technology to the Pfizer-BioNTech vaccine programme. In 2023, Karikó and Weissman were jointly awarded the Nobel Prize in Physiology or Medicine for their nucleoside modification discoveries — a recognition that implicitly validated the scientific centrality of their work to the entire COVID-19 mRNA vaccine enterprise.

Critics and researchers have noted the significance of the intellectual property pathway: foundational academic research, publicly funded in part through NIH grants, was patented and commercialised by private corporations — primarily Pfizer, BioNTech, and Moderna — generating unprecedented profits while governments and taxpayers bore the procurement costs and liability risks.

See also: MRNA Technology, COVID Vaccines, Lipid Nanoparticles, Moderna

Vaccine Mechanism and Deployment

The resulting product, BNT162b2, uses a lipid nanoparticle (LNP) delivery system to introduce synthetic mRNA encoding the SARS-CoV-2 spike protein into human cells, prompting an immune response. Unlike traditional vaccines using attenuated or inactivated pathogens, this represented the first mass-deployed application of mRNA technology in human medicine.

BNT162b2 received Emergency Use Authorisation (EUA) from the U.S. Food and Drug Administration (FDA) in December 2020, followed by full approval as Comirnaty in August 2021. The speed of development — under twelve months — was unprecedented in vaccine history and was facilitated through the U.S. government's Operation Warp Speed programme.

The vaccine was procured by governments worldwide at significant taxpayer expense. Pfizer's contracts with multiple governments included clauses — many obtained under freedom of information requests — indemnifying Pfizer against liability for adverse events, and in some cases requiring governments to pledge sovereign assets as collateral.

See also: COVID Vaccines, Lipid Nanoparticles, Anthony Fauci

Clinical Trial Data: The 75-Year Suppression Attempt

Following the FDA's full approval of BNT162b2, a group of scientists and physicians — operating as the Public Health and Medical Professionals for Transparency (PHMPT) — submitted a Freedom of Information Act (FOIA) request to the FDA demanding the release of the clinical trial data underpinning the vaccine's approval.

The FDA initially proposed releasing the data at a rate of approximately 500 pages per month, which would have taken an estimated 75 years to complete — meaning the full dataset would not be publicly available until around 2097. Critics argued this was a deliberate strategy to prevent independent scientific scrutiny during the period of maximum vaccine deployment.

In January 2022, U.S. District Judge Mark Pittman rejected the FDA's proposal and ordered accelerated disclosure, requiring the release of approximately 55,000 pages per month. The subsequent document releases became known informally as the Pfizer Documents.

Key findings from the released documents included:

  • A post-marketing adverse event report (Document 5.3.6 CUMULATIVE ANALYSIS) compiled by Pfizer in the first 90 days following EUA, listing over 1,200 deaths and 42,000 adverse event case reports across 158,000 adverse events — categorised by system organ class
  • Documentation that Pfizer was aware of a wide range of potential adverse effects, including myocarditis, pericarditis, Bell's palsy, anaphylaxis, stroke, thrombocytopenia, and numerous others, prior to widespread public rollout
  • Evidence that Pfizer had to temporarily hire additional staff to manage the volume of adverse event reports
  • Confidential manufacturing information regarding the composition of vaccine vials

These findings were circulated widely by researchers, journalists, and legal advocates, and formed the basis of several ongoing legal challenges in multiple jurisdictions.

Adverse Events and Post-Market Safety Signals

Independent analyses of post-market surveillance data — including the U.S. Vaccine Adverse Event Reporting System (VAERS), the UK Yellow Card system, and the European EudraVigilance database — identified safety signals not observed in comparable magnitude for any previously approved vaccine.

Reported serious adverse events included:

  • Myocarditis and pericarditis, particularly in young males following the second dose
  • Thrombosis with thrombocytopenia syndrome (TTS)
  • Neurological events including Guillain-Barré syndrome and transverse myelitis
  • Sudden cardiac death in previously healthy individuals
  • Menstrual irregularities and reproductive health concerns

Researchers including Ana Maria Mihalcea MD, PhD have drawn attention to apparent systemic patterns in these signals, arguing they are consistent with vascular and haematological disruption linked to spike protein expression and to undisclosed components in the vaccine formulation.

Independent Research: Anomalous Vial Contents

A number of independent scientists undertook direct physical and spectroscopic analysis of Pfizer-BioNTech vaccine vial contents. Their findings — which have not been published in mainstream peer-reviewed journals but have been widely circulated in the scientific dissident and TI-research communities — describe anomalous structures not disclosed in the official product formulation.

Dr. Pablo Campra

Dr. Pablo Campra, a researcher affiliated with the University of Almería in Spain, conducted micro-Raman spectroscopy analysis of COVID-19 vaccine samples. His published technical report (Graphene in COVID Vaccines) identified spectral signatures consistent with graphene oxide in vaccine vials. His findings were contested by mainstream authorities but have not been formally refuted through equivalent spectroscopic counter-analysis.

La Quinta Columna

La Quinta Columna, a Spanish research group led by Ricardo Delgado and Dr. José Luis Sevillano, was among the first to publicly advance the hypothesis that vaccine vials contained undisclosed graphene oxide. Their reports — citing microscopy and spectroscopy — claimed that graphene oxide constituted a significant proportion of the injectable contents and suggested a potential link to electromagnetic sensitivity, biocompatibility with nano-scale electronic systems, and adverse vascular events.

See also: Graphene Oxide, Ricardo Delgado

Dr. Ana Maria Mihalcea

Dr. Ana Maria Mihalcea, an internal medicine physician and researcher, has conducted live blood analysis and darkfield microscopy on blood samples from vaccinated individuals. Her published observations — available through her Substack and cited in several independent research compilations — describe:

  • Anomalous filamentous and crystalline structures in post-vaccination blood
  • Apparent self-assembling formations not present in unvaccinated control samples
  • Structures morphologically consistent with hydrogel scaffolding or nano-scale electronic components

Mihalcea has argued that these findings, taken together with the known properties of lipid nanoparticles and emerging research on DNA Nanotechnology, suggest the presence of an undisclosed nanotechnological payload in certain vaccine batches.

See also: Nanoparticles in Vaccines, Self-Assembling Nanostructures, Intra-Body Nano Network

Regulatory Capture and the FDA Relationship

Critics and researchers have pointed to a structural conflict of interest between Pfizer and the regulatory body responsible for its oversight.

The term Regulatory Capture describes a situation in which regulatory agencies come to serve the interests of the industries they are meant to regulate. Specific concerns raised in relation to Pfizer and the FDA include:

  • The revolving door between FDA personnel and the pharmaceutical industry: numerous senior FDA officials have subsequently taken positions at Pfizer or its contractors, and vice versa
  • The FDA's accelerated approval pathway for BNT162b2, which critics argue bypassed normal safety thresholds
  • The FDA's initial resistance to releasing clinical trial data — characterised by some legal commentators as acting as a co-litigant with Pfizer rather than as a neutral public health authority
  • The composition of the FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC), whose members have in several cases had financial ties to Pfizer or BioNTech

Anthony Fauci, as director of the National Institute of Allergy and Infectious Diseases (NIAID), played a central coordinating role in vaccine policy and had longstanding institutional relationships with pharmaceutical partners including Pfizer.

See also: Regulatory Capture, Anthony Fauci

Criminal History and Corporate Fraud

Pfizer has the distinction of having paid some of the largest criminal and civil fines in corporate history:

  • In 2009, Pfizer paid a record $2.3 billion settlement — the largest healthcare fraud settlement in U.S. Department of Justice history at that time — for illegally marketing the painkiller Bextra for off-label uses. The settlement included a $1.3 billion criminal fine, the largest ever levied against a company for any crime at the time.
  • Pfizer's subsidiary Pharmacia & Upjohn Company pled guilty to a felony charge of misbranding drugs with the intent to defraud and mislead.
  • Prior settlements included payments for illegal off-label promotion of Neurontin (gabapentin), Zyvox, and Geodon.
  • In multiple jurisdictions, Pfizer has been found to have engaged in kickback schemes to physicians and medical institutions in exchange for preferential prescribing.

Commentators note that these fines — while nominally large — represent a fraction of the revenues generated through the illegal conduct, effectively functioning as a cost of doing business rather than a deterrent.

Undisclosed Components and the Intra-Body Nano Network Hypothesis

Among the most contested claims surrounding Pfizer's COVID-19 vaccines is the hypothesis that certain batches contain nano-scale components capable of functioning within the body as part of a broader technological system — sometimes referred to as the Intra-Body Nano Network.

Proponents of this hypothesis — drawing on the independent vial analyses described above, the known capabilities of lipid nanoparticles as delivery vehicles, and emerging published research on DNA Nanotechnology and self-assembling nanostructures — argue that:

  • Lipid nanoparticle technology provides a viable delivery mechanism for nano-scale payloads
  • Graphene-based materials have documented biocompatibility and electromagnetic interaction properties relevant to nano-scale computing and communication
  • The MICS band and Body Area Network literature describes exactly the kind of intra-body communication infrastructure that would be required for a functioning biological nano-network
  • Unexplained self-assembling structures observed in post-vaccination blood samples are morphologically consistent with described nano-antenna or nano-processor architectures in the academic literature

This hypothesis remains outside mainstream scientific consensus. Proponents argue that the suppression of clinical data, the documented conflicts of interest in regulatory review, and the demonstrable anomalies in vial content analysis together constitute reasonable grounds for independent investigation.

See also: Intra-Body Nano Network, Self-Assembling Nanostructures, Graphene Oxide, Nanoparticles in Vaccines, Body Area Network

Pfizer and the Transhumanist Agenda

Some researchers situate Pfizer's activities — particularly its development and global deployment of mRNA technology — within a broader transhumanist agenda associated with institutions including the World Economic Forum, the Bill and Melinda Gates Foundation, and DARPA.

The argument holds that the mass deployment of injectable mRNA-LNP technology represents a step-change in the relationship between pharmaceutical biotechnology and the human body — normalising injectable nanotechnology and establishing regulatory and logistical infrastructure for future gene-modifying or body-area-network-enabling injections.

Pfizer CEO Albert Bourla has spoken publicly about the potential of mRNA technology to treat a wide range of diseases and conditions, framing vaccines as merely the first application of a broader therapeutic platform. Critics note that this platform — if extended to include gene editing, neuromodulation, or nano-sensor deployment — would represent a fundamental and potentially irreversible alteration of human biology. The foundational role of Katalin Karikó and Drew Weissman's nucleoside modification research in enabling this platform underscores how academic science — often publicly funded — has been channelled into a commercial and potentially geopolitical biotechnology infrastructure.

See also: Transhumanist Agenda, COVID-19 and the Transhumanist Agenda, MRNA Technology, DARPA Human Enhancement Programmes

See Also

References and Further Reading

  • Pfizer Post-Marketing Adverse Event Report (5.3.6), released under court order, January 2022
  • Campra, P. (2021). Graphene in COVID Vaccines: Micro-Raman spectroscopy analysis. University of Almería Technical Report.
  • PHMPT v. FDA, U.S. District Court, Northern District of Texas (2021–2022)
  • U.S. Department of Justice press release, Justice Department Announces Largest Health Care Fraud Settlement in Its History, September 2, 2009
  • Mihalcea, A.M. — Substack: Humanity United Now — Ana Maria Mihalcea, MD, PhD
  • La Quinta Columna — research bulletins and video reports, 2021–2023
  • Karikó, K. & Weissman, D. (2005). Suppression of RNA Recognition by Toll-like Receptors: The Impact of Nucleoside Modification and the Evolutionary Origin of RNA. Immunity, 23(2), 165–175.
  • Nobel Assembly at Karolinska Institutet (2023). Press Release: The Nobel Prize in Physiology or Medicine 2023 — Katalin Karikó and Drew Weissman.
Retrieved from "https://nanoworldorder.com/wiki/index.php?title=Pfizer&oldid=1929"